

NCIC CLINICAL TRIALS GROUP

BREAST

DISEASE SITE COMMITTEE MEETING AGENDA

FAIRMONT QUEEN ELIZABETH HOTEL, MONTREAL, QC

ROOM: MARQUETTE

SUNDAY, MAY 2, 2010 – 8:00 AM – 1:00 PM

CO-CHAIRS: T. WHELAN / K. GELMON

8:00 am	Welcome , Introductions, Comments	T. Whelan/K. Gelmon
8:05 am	Report from Site Review – CCSRI	T. Whelan/K. Gelmon
8:15 am	New / Pending Trials: <ul style="list-style-type: none">MA.32 (Metformin + Fatigue Sub-Study)	P. Goodwin
8:25 am	Open Trials: <ul style="list-style-type: none">MA.31 (Lapatinib vs Trastuzumab in Metastatic)MA.33 (TROG 07.01: Non-low risk DCIS of breast)	K. Gelmon I. Olivotto
8:45 am	Closed Trials: <ul style="list-style-type: none">MA.17R (Letrozole vs Placebo after AI)MA.20 (Regional Radiation Therapy in Early Breast Cancer)MA.21 (Adjuvant Chemo)MA.22 (Epi + Docetaxel + Pegfilgrastim, locally advanced)MA.24 and Trans-HERAMA.27, MA.27B, MA.27D (Exemestane vs Anastrozole)MA.29 (Pre-Operative Sunitinib – SU11248)MAP.3 (Exemestane vs Placebo – Prevention)	L. Shepherd/P. Goss T. Whelan M. Burnell M. Trudeau K. Gelmon L. Shepherd/P. Goss M. Trudeau L. Shepherd/P. Goss
10:00 am	<i>Coffee Break</i>	
10:10 am	IND Trials: <ul style="list-style-type: none">IND.197 (Phase II Foretinib in ER/PgR & HER2 Neg Recurrent/Metastatic)IND.198 (Phase I/II Foretinib & Lapatinib in HER2 + Metastatic)	D. Rayson S. Chia
10:30 am	Trial Proposals: <ul style="list-style-type: none">ECOG Triple Negative StudyLuminal BNeoadjuvant IGFR-1 InhibitorsSurgical ProposalPARP Inhibitor	S. Ellard S. Ellard M. Basik M. Basik R. Dent

continued on next page ...

